TECHWIRE 30
(CIX: WRAL30)  1,059.57  down arrow-0.48  (-0.05 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Apple)  102.99  up arrow+0.52  (0.51 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: QUINTILES)  56.55  up arrow+0.05  (0.09 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: BASF SE)  87.84  down arrow-1.17  (-1.31 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: BioCryst)  11.70  up arrow+0.33  (2.9 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: BioDelivery)  15.90  down arrow-0.45  (-2.75 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: CEMP)  11.88  down arrow-0.31  (-2.54 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: Cisco Systems)  23.26  down arrow-0.25  (-1.06 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: Cree)  27.28  down arrow-5.87  (-17.71 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: DARA)  0.90  up arrow+0.03  (3.44 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: EMC CORPORATION)  27.37  up arrow+0.17  (0.63 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Extreme Networks)  3.01  down arrow-0.19  (-5.94 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: FB)  78.37  down arrow-0.32  (-0.41 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: GLAXOSMITHKLINE)  44.41  up arrow+0.78  (1.79 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: GOOG)  532.71  up arrow+6.17  (1.17 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: IBM)  161.79  down arrow-1.44  (-0.88 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NY: LH)  101.07  down arrow-0.23  (-0.23 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: Lenovo Group)  28.95  down arrow-0.07  (-0.24 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: MRK)  55.51  up arrow+0.38  (0.69 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Microsoft Corp)  44.38  down arrow-0.5  (-1.11 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: NTAP)  39.66  up arrow+0.39  (0.99 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: NOVARTIS AG)  88.20  down arrow-0.41  (-0.46 %)  Updated: 06:40 PM EDT, Oct 22 2014
(OP: Novozymes A/S)  40.92  down arrow-0.17  (-0.4 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: PFIZER)  28.30  up arrow+0.02  (0.07 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: Pozen)  8.47  up arrow+0.2  (2.42 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NY: RED HAT)  54.80  down arrow-2.33  (-4.08 %)  Updated: 06:40 PM EDT, Oct 22 2014
(NQ: BBRY)  9.89  down arrow-0.26  (-2.56 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: Salix)  137.61  down arrow-2.94  (-2.09 %)  Updated: 05:20 PM EDT, Oct 22 2014
(NQ: SQI)  15.21  down arrow-0.12  (-0.78 %)  Updated: 05:20 PM EDT, Oct 22 2014

Posts tagged “Chimerix ”

3:07 p.m. yesterday

GSK's Ebola vaccine could be tested in January, WHO says

Ebola Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.

Updated October 16

Durham-based Chimerix speeds up Ebola testing

Ebola Chimerix says it has FDA approval to launch a Phase 2 clinical trial of its possible treatment for Ebola. The drug has already been administered to two Ebola patients, one of whom died. The new trial will test safety, tolerability and efficacy for Brincidofovir.

Updated October 8

Ebola patient treated with experimental drug from Durham firm dies

Ebola Outbreak The first Ebola patient diagnosed in the United States died in a Dallas hospital Wednesday, a little more than a week after his illness exposed gaps in the nation's defenses against the disease and set off a scramble to track down anyone exposed to him.

October 8

Journalist stricken with Ebola also receives experimental Chimerix drug

Ebola Outbreak Durham-based Chimerix is providing its experimental antiviral drug to a journalist in Nebraska. A Dallas patient also being treated for Ebola received the treatment earlier.

October 7

#WTWTrends for Tuesday: Nobel Prize, Chimerix, INC and Canes trending in the Triangle

Trending in the Triangle Trending in the Triangle: Get the pulse of technology in the Triangle with the best in local technology, venture, biotech, and life science news on Tuesday, Oct. 7, 2014 as curated by @WRALTechWire.

October 7

Experimental Chimerix drug given to Ebola patient in Dallas

Durham-based Chimerix is providing its experimental antiviral drug to a Dallas patient being treated for Ebola, an emergency step authorized by the Food and Drug Administration. The move came Monday after the FDA authorized Chimerix to accelerate testing of its antiviral treatment.

How Chimerix anti-virals work How Chimerix anti-virals work

Updated October 6

FDA fast-tracks testing of Durham firm's Ebola treatment

The Food and Drug Administration is accelerating testing of a potential treatment for the Ebola virus that is being developed by Durham-based Chimerix. Currently there is no cure for the virus, which has killed more than 3,000 people in West Africa.

How Chimerix anti-virals work How Chimerix anti-virals work

Updated July 16

Premium Lock Josh Hardy, treated with experimental Chimerix drug, is going home

Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Josh Hardy, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy in March. On Wednesday, his mother said he is doing well and going home.

Josh Hardy Josh Hardy

May 2

Premium Lock Durham firm's good FDA news; Chimerix eyes $200M; SEAL Innovation expands; Snapchat adds chat; eBay settles antitrust case

Bulldog In today's Bulldog blog roundup of technology and life science news, get the latest about drug firm Parion Sciences, a $200 million stock offering from Chimerix, details about Raleigh-based startup SEAL Innovation's expansion, Snapchat finally adds chat, and eBay settles an antitrust case.

April 9

Premium Lock Chimerix names new CEO after Moch steps down

Chimerix Kenneth Moch has resigned as chief executive of the biopharmaceutical company to "pursue other interests," the company announced on Wednesday while also naming his replacement.

Updated March 19

Premium Lock Window of opportunity: More life science IPOs in Triangle is good for all

Life Sciences A spate of Triangle life science IPOs raised more total money than those in Boston and New York in 2013, and more followed early this year. Has this open IPO window affected biotech and life science fundraising in the Triangle? Will the window remain open? One area VC suggests we may look back on 2010-2015 as a watershed time for the regional industry.

March 12

Premium Lock Experimental Chimerix drug request granted for sick boy

Chimerix, the Durham-based drug company working on experimental medicine that could save the life of a seven-year-old Virginia child, was granted approval by the U.S. Food and Drug Administration to administer the drug to the boy, the company said Tuesday evening.

Josh Hardy Josh Hardy

Updated February 28

Premium Lock IPO Watch: Scynexis joins Square 1 in pipeline of Triangle firms going public

Wall Street Quintiles led the class of Triangle IPOs in the last year at nearly $1 billion in value, but ChannelAdvisor's stock is showing remarkable strength. So is Aerie Pharmaceuticals. With Scynexis filing to go public Thursday, WRALTechWire updates what has happened on the stock "exit route" for regional firms and how their stocks have fared since.

Updated October 25, 2013

Premium Lock Aerie Pharma cuts stock price, adds shares for $67M IPO; Chimerix sells more stock

Aerie Pharmaceuticals Aerie Pharmaceuticals' $67 million IPO was priced at $10 per share, well below the $12 to $14 per share range the company had previously set. Read more about the offering.

October 8, 2013

Premium Lock 'Certain' Chimerix stockholders plan to sell shares

Chimerix Chimerix, a Durham-based drug developer that went public in April for more than $100 million, says in an SEC filing that "certain stockholders" are looking to sell their shares.

May 13, 2013

Premium Lock Durham drug firm Chimerix reports $9.1M quarterly loss

Chimerix The company, which went public in April, reports a drop in revenue and an increase in expenses. But stock rallies 4 percent on the news.

Updated December 10, 2012

Premium Lock Chemistry among people, companies is crucial to biochemistry deals

Finding the right chemistry is crucial to biotech deals, as two major life science partnerships in the Triangle have shown this year: GSK and Liquidia; Merck and Chimerix.

Drug deal Drug deal

November 12, 2012

Premium Lock RTP drug firm Chimerix names former GSK exec as chief medical officer

Chimerix Dr. Michelle Berrey, MD, joins the firm from Pharmasset where she also served as CMO. Pharmasset was acquired by Gilead Sciences earlier this year.

July 25, 2012

Premium Lock Merck licenses HIV compound from RTP-based Chimerix

Fighting HIV In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Frank Vinluan
Life science
Scroll